A Study of Recombinant Human Growth Hormone Injection for Short Children

Updated 04/30/2024

Status Recruiting

Clinical Trial Summary

According to the results of the phase II study, choose the best dose of JINTOPIN AQ for short SGA children, further to evaluate the efficacy and safety of the treatment of short SGA children.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Small for Gestational Age Infant

Clinical Trial Details

NCT number	NCT03245333
Study type	Interventional
Source	GeneScience Pharmaceuticals Co., Ltd.
Contact	Xiaohua Feng
Phone	0431-85170552
Email	fengxiaohua@gensci-china.com
Status	Recruiting
Phase	Phase 3
Start date	December 2014

See also
	Status	Clinical Trial	Phase
	Completed	`NCT05059093` - Developing and Testing AI Models for Fetal Biometry and Amniotic Volume Assessment in Fetal Ultrasound Scans.
	Recruiting	`NCT02375620` - Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat SGA Children With Short Stature	Phase 2
	Not yet recruiting	`NCT05043753` - "Fetal gRowth AbnorMality dEtection Trial"	N/A
	Not yet recruiting	`NCT05070234` - Genetic Diagnosis and Human Growth Hormone Treatment in Small for Gestational Age Children With Short Stature
	Active, not recruiting	`NCT05343403` - Parental Participation on the Neonatal Ward - the neoPARTNER Study
	Not yet recruiting	`NCT05436119` - Select Nutrient and Gene Variant Analysis in a Targeted Diet and Lifestyle Intervention Reduces Preterm Birth
	Recruiting	`NCT04315545` - Pregnancy Outcomes and Maternal Insulin Sensitivity
	Completed	`NCT03221933` - A Study of Recombinant Human Growth Hormone Injection（JINTOPIN AQ）for Short Children With Small for SGA	Phase 2
	Not yet recruiting	`NCT04050488` - Zinc Supplementation on Very Low Birth Weight Infant	Phase 4
	Recruiting	`NCT05144035` - A Real World Study of the Effect of Early PEG-rhGH Therapy on Cognitive Development of SGA Infants	Phase 4